Fluicell Receives Green Light With a New BioPen Patent in the USA
STOCKHOLM, June 14, 2017/PRNewswire/ -- Fluicell AB is extremely pleased to announce the approval from the USPTO, of Patent No. 9,658,240, entitled 'Microfluidic device with holding interface, and methods of use'. This is the second patent approved for their transformational BioPen product line, which facilitates complex cell biology experiments at single-cell level, at affordable prices. This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell biology research and discovery tools for the 21st century.
For further information, please visit us at: fluicell.comor contact: Victoire Viannay CEO Tel: +46-725-65-42-05 E-mail: [email protected]
About Fluicell
Fluicell is an exciting Swedish high-tech company that brings inspiration and innovation to life science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, bioprinting, and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces costs, resource use, and animals.Fluicell's main target sectors include universities, the pharmaceutical industry, and national health laboratories.
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps.
Designed to address...
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards.
"This product, along with our other innovations,...
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...